The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Open accessAbstract
Cell cycle checkpoints appear to contribute to an increase in cell survival and a decrease in abnormal heritable genetic changes following exposure to DNA damaging agents. Though several radiation-sensitive yeast mutants have been identified, little is known about the genes that control these responses in mammalian cells. Recent studies from our laboratory have demonstrated a close correlation between expression of wild-type p53 genes in human hematopoietic cells and their ability to arrest in G1 phase after certain types of DNA damage. In the present study, this correlation was first generalized to nonhematopoietic mammalian cells as well. A cause and effect relationship between expression of wild-type p53 and the G1 arrest that occurs after gamma irradiation was then established by demonstrating (i) acquisition of the G1 arrest after gamma irradiation following transfection of wild-type p53 genes into cells lacking endogenous p53 genes and (ii) loss of the G1 arrest after irradiation following transfection of mutant p53 genes into cells with wild-type endogenous p53 genes. A defined role for p53 (the most commonly mutated gene in human cancers) in a physiologic pathway has, to our knowledge, not been reported previously. Furthermore, these experiments illustrate one way in which a mutant p53 gene product can function in a "dominant negative" manner. Participation of p53 in this pathway suggests a mechanism for the contribution of abnormalities in p53 to tumorigenesis and genetic instability and provides a useful model for studies of the molecular mechanisms of p53 involvement in controlling the cell cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Self-citationCheckpoints: Controls That Ensure the Order of Cell Cycle Events
Hartwell, L. H., & Weinert, T. A. (1989) · Science · doi:10.1126/science.2683079 · Cited by 3,021
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,066
The p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,754
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Cell Proliferation in Carcinogenesis
Cohen, S. M., & Ellwein, L. B. (1990) · Science · doi:10.1126/science.2204108 · Cited by 1,050
Increased cell division as a cause of human cancer.
Preston‐Martin, S., Pike, M. C., Ross, R. K., Jones, P. A., & Henderson, B. E. (1990) · PubMed · Cited by 896
Cited by
Items 101–158 of 158
Ford, J. M., & Hanawalt, P. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8876 · Cited by 346
Hypermethylation of the DAP-Kinase CpG Island Is a Common Alteration in B-Cell Malignancies
Katzenellenbogen, R. A., Baylin, S. B., & Herman, J. G. (1999) · Blood · doi:10.1182/blood.v93.12.4347 · Cited by 345
Slebos, R. J., Lee, M. H., Plunkett, B. S., Kessis, T. D., Williams, B. O., Jacks, T., Hedrick, L., Kastan, M. B., & Cho, K. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5320 · Cited by 344
Self-citationp53-mediated cell death: relationship to cell cycle control.
Yonish-Rouach, E., Grunwald, D., Wilder, S., Kimchi, A., May, E., Lawrence, J. J., May, P., & Oren, M. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.3.1415 · Cited by 344
Evan, G. I., Brown, L., Whyte, M., & Harrington, E. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80066-2 · Cited by 336
Barone, M. V., Crozat, A., Tabaee, A., Philipson, L., & Ron, D. (1994) · Genes & Development · doi:10.1101/gad.8.4.453 · Cited by 336
Liu, Y., Zhang, P., Li, F., Jin, X., Li, J., Chen, W., & Li, Q. (2018) · Theranostics · doi:10.7150/thno.22172 · Cited by 335
The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation
SOUSSI, T. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06705.x · Cited by 332
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328
“The activity of p53 is potentiated in normal cells following DNA damage (Maltzman and Czyzyk 1984; Kastan et al. 1991, 1992; Kuerbitz et al. 1992; Fritsche et al. 1993; Lu and Lane 1993; Zhan et al. 1993).”
BackgroundHow does radiation kill cells?
Cohen–Jonathan, E., Bernhard, E. J., & McKenna, W. G. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80014-3 · Cited by 328
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
(1993) · PubMed · Cited by 323
Signal Transduction and Cellular Radiation Responses
Schmidt-Ullrich, R. K., Dent, P., Grant, S., Mikkelsen, R. B., & Valerie, K. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0245:stacrr]2.0.co;2 · Cited by 316
Photochemoprevention of ultraviolet B signaling and photocarcinogenesis
Afaq, F., Adhami, V. M., & Mukhtar, H. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.07.019 · Cited by 310
Mass, M. J., & Wang, L. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(97)00008-2 · Cited by 309
Ubiquitination of p53 and p21 Is Differentially Affected by Ionizing and UV Radiation
Maki, C. G., & Howley, P. M. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.1.355 · Cited by 308
Allosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 301
Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.
Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., & Vousden, K. H. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00418.x · Cited by 301
Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer
(1997) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60095-0 · Cited by 300
Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts
Pagano, M., Theodoras, A. M., Tam, S. W., & Draetta, G. F. (1994) · Genes & Development · doi:10.1101/gad.8.14.1627 · Cited by 294
The molecular basis for cell cycle delays following ionizing radiation: a review
Maity, A., McKenna, W. G., & Muschel, R. J. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90408-1 · Cited by 294
DNA repair in the extremely radioresistant bacterium Deinococcus radiodurans
Minton, K. W. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00397.x · Cited by 290
Negative feedback regulation of wild-type p53 biosynthesis.
Mosner, J., Mummenbrauer, T., Bauer, C., Sczakiel, G., Grosse, F., & Deppert, W. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00123.x · Cited by 286
Genetic background alters the spectrum of tumors that develop in p53‐deficient mice
Harvey, M., McArthur, M. J., Montgomery, C. A., Bradley, A., & Donehower, L. A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.10.8344491 · Cited by 285
Murray, A. (1994) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(94)90059-0 · Cited by 282
Inhibition of apoptosis by the retinoblastoma gene product.
Haas-Kogan, D. A., Kogan, S. C., Levi, D., Dazin, P., T'Ang, A., Fung, Y. K., & Israel, M. A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07022.x · Cited by 281
A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis
Friedlander, P., Haupt, Y., Prives, C., & Oren, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4961 · Cited by 278
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
Ma, C. X., Janetka, J. W., & Piwnica-Worms, H. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.009 · Cited by 271
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271
Self-citationPowell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., Tang, W., & Friend, S. H. (1995) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)97825-l · Cited by 268
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994) · Current Opinion in Genetics & Development · doi:10.1016/0959-437x(94)90100-7 · Cited by 265
Krüppel-like Factor 4 Mediates p53-dependent G1/S Cell Cycle Arrest in Response to DNA Damage
Yoon, H. S., Chen, X., & Yang, V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211027200 · Cited by 265
Minn, A. J., Boise, L. H., & Thompson, C. B. (1996) · Genes & Development · doi:10.1101/gad.10.20.2621 · Cited by 263
Photocarcinogenesis: an overview
Black, H. S., deGruijl, F. R., Forbes, P. D., Cleaver, J. E., Ananthaswamy, H. N., deFabo, E. C., Ullrich, S. E., & Tyrrell, R. M. (1997) · Journal of Photochemistry and Photobiology B: Biology · doi:10.1016/s1011-1344(97)00021-3 · Cited by 260
Milne, D. M., Campbell, L. E., Campbell, D. G., & Meek, D. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5511 · Cited by 257
Cell cycle control, checkpoint mechanisms, and genotoxic stress.
Shackelford, R. E., Kaufmann, W. K., & Paules, R. S. (1999) · Environmental Health Perspectives · doi:10.1289/ehp.99107s15 · Cited by 257
Tebbs, R. S., Zhao, Y., Tucker, J. D., Scheerer, J. B., Siciliano, M. J., Hwang, M., Liu, N., Legerski, R. J., & Thompson, L. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6354 · Cited by 257
Fries, K. L., Miller, W. E., & Raab-Traub, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8653-8659.1996 · Cited by 255
The role of BRCA1 in DNA damage response
Wu, J., Lu, L.-Y., & Yu, X. (2010) · Protein & Cell · doi:10.1007/s13238-010-0010-5 · Cited by 235
“The tumor suppressor p53 plays a critical role in DNA damage-induced G1/S checkpoint by controlling cyclin inhibitor p21’s transcription (Kuerbitz et al., 1992; Dulic et al., 1994; Reed et al., 1994).”
BackgroundChen, C.-F., Chen, P.-L., Zhong, Q., Sharp, Z. D., & Lee, W.-H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.46.32931 · Cited by 207
Inhibition of p53 DNA binding by human papillomavirus E6 proteins
Lechner, M. S., & Laimins, L. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4262-4273.1994 · Cited by 195
Demers, G. W., Foster, S. A., Halbert, C. L., & Galloway, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4382 · Cited by 172
Requirement for p27KIP1 in Retinoblastoma Protein-Mediated Senescence
Alexander, K., & Hinds, P. W. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.11.3616-3631.2001 · Cited by 164
Foster, S. A., Demers, G. W., Etscheid, B. G., & Galloway, D. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5698-5705.1994 · Cited by 160
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
“Median age, years (range) 58 (42–77) 60 (40–80) Race, n (%) White 53 (90) 52 (84) Asian 5 (9) 8 (13) American Indian/Alaskan native 1 (2) 1 (2) Black/African American 0 1 (2) ECOG performance status, n (%) 0 38 (64) 35 (57) 1 21 (36) 27 (44) Primary tumor location, n (%) Ovary 55 (93) 53 (85) Fallopian tube or primary…”
Background(1999) · PubMed · Cited by 123
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
Regulation of DNA damage recognition and nucleotide excision repair: another role for p53
Ford, J. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.04.005 · Cited by 117
Bachtiary, B., Obermair, A., Dreier, B., Birner, P., Breitenecker, G., Knocke, T., Selzer, E., & Pötter, R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10708 · Cited by 101
Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation
ZHAN, Q., FAN, S., SMITH, M. L., BAE, I., YU, K., ALAMO, I., O'CONNOR, P. M., & FORNACE, A. J. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.805 · Cited by 97
Tong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
“Enhanced expression of p53 results either in G1 arrest of these cells (Smith et al., 1994; Kuerbitz et al., 1992; Wang et al., 1998; Allan and Fried, 1999) or drives the cells toward apoptosis (Debbas and White, 1993; Lowe et al., 1993; Allan and Fried, 1999; Huang et al., 2001).”
BackgroundRetractedLoss of Fas-Ligand Expression in Mouse Keratinocytes during UV Carcinogenesis
Ouhtit, A., Gorny, A., Muller, H. K., Hill, L. L., Owen-Schaub, L., & Ananthaswamy, H. N. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64836-5 · Cited by 82
Wang, H., Yu, D., Agrawal, S., & Zhang, R. (2003) · The Prostate · doi:10.1002/pros.10187 · Cited by 78
Li, J., Wu, J., Bao, X., Honea, N., Xie, Y., Kim, S., Sparreboom, A., & Sanai, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0983 · Cited by 68
“Because the tumor suppressor protein p53 regulates the G1 checkpoint, cancer cells harboring abnormalities in the p53 pathway becomemore dependent onG2 and S checkpoints in cell-cycle control (9, 13), and, therefore, p53deficient cancer cells treated with Wee1 inhibitors would be particularly susceptible to DNA damage…”
BackgroundHalazonetis, T. D. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.036 · Cited by 53
Genetic variation in radiation-induced cell death
Smirnov, D. A., Brady, L., Halasa, K., Morley, M., Solomon, S., & Cheung, V. G. (2012) · Genome Research · doi:10.1101/gr.122044.111 · Cited by 46
Novoa, B., Pereiro, P., López‐Muñoz, A., Varela, M., Forn‐Cuní, G., Anchelin, M., Dios, S., Romero, A., Martinez‐López, A., Medina‐Gali, R. M., et al. (2019) · Aging Cell · doi:10.1111/acel.13020 · Cited by 41
Saito, Y., Gopalan, B., Mhashilkar, A. M., Roth, J. A., Chada, S., Zumstein, L., & Ramesh, R. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700644 · Cited by 33
Metadata
- Authors
- Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-08-15
- Volume
- 89
- Issue
- 16
- Pages
- 7491-7495
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2030283142
- Cited by
- 1,837
- References
- 26
- FWCI
- 67.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.